Lenalidomide eliminated transfusion dependence for a minority of non-del(5q) MDS patientsJune 29, 2016Myelodysplastic Syndrome
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabineApril 13, 2016Myelodysplastic SyndromeAML
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabineApril 13, 2016Myelodysplastic SyndromeAML
In myelodysplastic syndrome, improved tool for predicting death after HCTApril 11, 2016Myelodysplastic SyndromeAMLCellular Therapy
Medicare to cover HSCT in approved clinical trials for myeloma, myelofibrosis, sickle cell diseaseJanuary 28, 2016Myelodysplastic SyndromeAnemiaMultiple MyelomaCellular TherapyBusiness of Medicine
VIDEO: High-intensity conditioning stands ground in MDS, AMLDecember 8, 2015AMLMyelodysplastic Syndrome
Heme Themes: Transplant timing for myelofibrosis in the era of JAK2 inhibitorsSeptember 3, 2015Myelodysplastic SyndromeTransfusion Medicine
Heme Themes: Challenges in averting the progression of MPN, MDSSeptember 3, 2015Myelodysplastic Syndrome
Imetelstat elicits response in myelofibrosis, thrombocythemiaSeptember 2, 2015Myelodysplastic SyndromeTranslational Research
CD8 cell dose predicts outcomes in allogeneic stem cell transplantation with reduced-intensity conditioningJune 8, 2015Myelodysplastic SyndromeAMLCellular Therapy
ASCO: PERSIST-1 – pacritinib tops best available therapy in myelofibrosisJune 5, 2015Myelodysplastic Syndrome
Dexrazoxane Tx did not affect overall survival in pediatric leukemia and lymphomaMay 26, 2015AMLMyelodysplastic Syndrome
